about
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsEx vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Combination immunotherapy: a road map.New development in CAR-T cell therapy.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Adoptive Cell Therapy in Multiple Myeloma.Bioengineering solutions for manufacturing challenges in CAR T cells.Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Cancer Immunotherapy: Whence and Whither.Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.Tumor-targeting domains for chimeric antigen receptor T cells.The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.CAR T-cell therapy for pancreatic cancer.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.Cancer immunotherapy: Breakthrough or "deja vu, all over again"?PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Do hospitals need oncological critical care units?A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members.Clinical trials of CAR-T cells in ChinaAnti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.Next frontiers in CAR T-cell therapy.Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation.Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.Chimeric antigen receptor T-cell therapies for multiple myeloma.The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
P2860
Q33823270-9C9112D3-7694-4CDD-9844-7B97A6D62A72Q33833475-749A4773-A70B-4E61-838D-BE5D796ED237Q33861833-BFE024D7-8EFC-436A-859D-DF2521793917Q34552128-13163F13-C7ED-4487-B303-5A9E6769D9E2Q37658246-567EC77F-9A2A-4381-A843-0462059A37A9Q37728639-36D1A33B-A7C2-450D-AD2E-12437E5852F7Q38635138-5BC0D79E-41CA-4CC4-9D51-796537CB9BF4Q38637370-1FC1D01A-AC09-4546-8DCD-270F6BF1718FQ38649517-E625C4A6-4706-4B10-9092-377286D06E9BQ38666579-7CABBB3D-36DD-4FCA-9A81-A06CB6B01783Q38737924-D3014ED1-6AF6-4958-BA8E-E95682E4BA3AQ38743043-A0F88B19-05E5-41C4-BBD6-DAB03D94EEB3Q38748836-BA67AE4F-56A0-47F8-B159-B7A9CA917117Q39045535-747ED4F8-447C-4BBD-B90E-D5D38C42F40BQ39115858-DB3170E4-434F-4EAE-8153-E48A539CE49BQ39202440-D7515F7E-5B05-4ABE-9C44-05A307499653Q39280002-F5C539A2-B2E0-4657-BAEF-804237EBCC78Q39301512-E27304C6-8501-451D-BB79-00FCC1C80B4FQ39390619-967DCB77-E244-4F1E-A00F-26096515BF9CQ39420466-D0AA9376-71C6-4170-8801-8A3FB6C1AA43Q41928232-14E5E016-3A0C-4512-8E81-A94FF1449DF0Q42362328-51263852-4381-468C-9C85-F78AFB2587F3Q42378925-BD364233-9A1F-449A-B653-0D49A850072CQ42654456-D8CB81BD-B756-433B-A7B4-18898449D9B1Q45871879-D37BA361-62CA-4A08-8BFC-A2F2B7E7CCE5Q45947690-3E668523-63B6-4CE9-8A43-FE2941094C1FQ46082373-EC0AA85A-DF74-40A2-BC83-B8F2097E287EQ46848787-F4A72D5A-83D3-401E-9689-71A06D8BCBD9Q47150746-8EF6E928-B7CA-4574-9580-ED12DFBF49BEQ47159409-E8EBC90A-B6A5-4168-95DA-7B4B49A5E49EQ47201278-2B5E757D-F0CF-41CA-8C62-F75DBA3E14D0Q47355616-1AB6504F-38DA-473C-801C-175DE248889EQ47377609-2E4E962F-177D-48D8-9C21-CBB10F6050C1Q47406496-76D749C2-AD8C-439C-973E-38328814886CQ47681829-A3C71513-B55C-40C5-A5FC-88E4129C8070Q47709474-1DE08473-0925-4C2D-8AB3-AF122E65497CQ47718243-F7180CFA-21D0-433C-9330-8D0972605EF1Q47776210-72613BB7-7D20-4458-9840-76EF2119E308Q47809709-B6B6020C-E821-481A-9887-F0E2D0061D48Q47821811-A6C67AD3-6AC0-45BD-A6A5-676A2289202D
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Toxicity and management in CAR T-cell therapy
@ast
Toxicity and management in CAR T-cell therapy
@en
Toxicity and management in CAR T-cell therapy
@nl
type
label
Toxicity and management in CAR T-cell therapy
@ast
Toxicity and management in CAR T-cell therapy
@en
Toxicity and management in CAR T-cell therapy
@nl
prefLabel
Toxicity and management in CAR T-cell therapy
@ast
Toxicity and management in CAR T-cell therapy
@en
Toxicity and management in CAR T-cell therapy
@nl
P2093
P2860
P3181
P356
P1476
Toxicity and management in CAR T-cell therapy
@en
P2093
Challice L Bonifant
Hollie J Jackson
Kevin J Curran
Renier J Brentjens
P2860
P3181
P356
10.1038/MTO.2016.11
P407
P577
2016-04-20T00:00:00Z